Top

Published in:

01-05-2014 | Gastrointestinal Oncology

Peritoneal Carcinomatosis in T4 Colorectal Cancer: Occurrence and Risk Factors

Authors: H. C. van Santvoort, MD, PhD, H. J. Braam, MD, K. R. Spekreijse, MD, N. R. Koning, MD, P. C. de Bruin, MD, PhD, T. S. de Vries Reilingh, MD, PhD, D. Boerma, MD, PhD, A. B. Smits, MD, PhD, M. J. Wiezer, MD, PhD, B. van Ramshorst, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2014

Abstract

Background

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves outcome of patients with peritoneal carcinomatosis (PC) of colorectal carcinoma. Data on the occurrence of PC in T4 colorectal carcinoma are scarce. We investigated the occurrence and risk factors for PC in these patients.

Methods

This was a retrospective cohort study of patients undergoing a first resection of a T4 colorectal carcinoma in a tertiary hospital between January 2000 and December 2007. Primary outcome was the occurrence of synchronous or metachronous PC. The association with PC and several patient and tumor characteristics was evaluated using logistic regression.

Results

A total of 200 patients underwent resection of a T4 colorectal carcinoma. Median follow-up censored for death was 66 months (18–89 months). Synchronous PC was found in 46 of 200 patients (23 %) and metachronous PC in 33 of 154 patients (21 %). In univariable analysis, factors associated with PC were: age (OR 0.97; 95 % CI 0.94–0.99; P = 0.03), radical resection (OR 0.32; 95 % CI 0.11–0.91; P = 0.03), and N stage (OR 1.63; 95 % CI 1.36–2.34; P = 0.008). In multivariable analysis, only N stage was associated with PC (OR 1.62; 95 % CI 1.12–2.34; P = 0.01). This association was not significant for the 154 patients at risk for metachronous PC.

Conclusions

Around 1 in 5 patients undergoing resection of a T4 colorectal carcinoma either have PC during primary resection or develop PC during follow-up. N stage was associated with PC in the entire study population. However, none of the clinical or pathological variables were associated with the risk of metachronous PC and therefore cannot be used to develop targeted surveillance strategies.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Accessed 15 Jan 2013.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef

Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.PubMedCrossRef

Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212–22.PubMedCentralPubMedCrossRef

Honoré C, Goéré D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183–92.PubMedCrossRef

Hagendoorn JA, van Lammeren G, Boerma D, van der Beek E, Wiezer MJ, van Ramshorst B. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival. Eur J Surg Oncol. 2009;35:833–7.PubMedCrossRef

Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia. 2007;23:431–42.PubMedCrossRef

Caplin S, Cerottini JP, Bosman FT, Constanda MT, Givel JC. For patients with Dukes’ B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer. 1998;83:666–72.PubMedCrossRef

10.

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32. PubMedCrossRef

11.

de Cuba EM, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 2013;39:321–7.PubMedCrossRef

12.

Schmoll HJ, van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–516.PubMedCrossRef

13.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.CrossRef

14.

Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Contr Clin Trials. 1996;17:343–6.CrossRef

15.

Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99:699–705. doi:10.1002/bjs.8679.PubMedCrossRef

16.

Katoh H, Yamashita K, Sato T, Ozawa H, Nakamura T, Watanabe M. Prognostic significance of peritoneal tumour cells identified at surgery for colorectal cancer. Br J Surg. 2009;96:769–77.PubMedCrossRef

17.

Verwaal VJ, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11:375–9.PubMedCrossRef

18.

Elias D, Glehen O, Pocard M, Quenet F, Goéré D, Arvieux C, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251:896–901.PubMedCrossRef

19.

Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMedCrossRef

20.

Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.PubMedCrossRef

21.

Elias D, Goéré D, Di Pietrantonio D, Boige V, Malka D, Kohneh-Shahri N, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008;247:445–50.PubMedCrossRef

22.

ClinicalTrials.gov. Trial comparing simple follow-up to exploratory laparotomy plus ‘in Principle’ (hyperthermic intraperitoneal chemotherapy) HIPEC in colorectal patients (ProphyloCHIP). 2011. http://clinicaltrials.gov/ct2/show/NCT01226394. Accessed 4 Oct 2011.

23.

Winget M, Hossain S, Yasui Y, Scarfe A. Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Cancer. 2010;116:4849–56.PubMedCrossRef

24.

Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005;294:2703–11. PubMedCrossRef

Title: Peritoneal Carcinomatosis in T4 Colorectal Cancer: Occurrence and Risk Factors
Authors: H. C. van Santvoort, MD, PhD
H. J. Braam, MD
K. R. Spekreijse, MD
N. R. Koning, MD
P. C. de Bruin, MD, PhD
T. S. de Vries Reilingh, MD, PhD
D. Boerma, MD, PhD
A. B. Smits, MD, PhD
M. J. Wiezer, MD, PhD
B. van Ramshorst, MD, PhD
Publication date: 01-05-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 5/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-3461-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Peritoneal Carcinomatosis in T4 Colorectal Cancer: Occurrence and Risk Factors

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2014

Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States

High Expression of Glucose Transporter 1 on Primary Lesions of Esophageal Squamous Cell Carcinoma is Associated with Hematogenous Recurrence

Neoadjuvant Chemotherapy for Localized Pancreatic Cancer: Too Little or Too Long?

In Memoriam: Donald L. Morton, MD (1934–2014): An Icon in Surgical Oncology

Sentinel Lymph Node Biopsy is Associated with Improved Survival in Merkel Cell Carcinoma

Hypoxia in Melanoma: Using Optical Spectroscopy and EF5 to Assess Tumor Oxygenation Before and During Regional Chemotherapy for Melanoma